Target Name: FUCA1
NCBI ID: G2517
Review Report on FUCA1 Target / Biomarker Content of Review Report on FUCA1 Target / Biomarker
FUCA1
Other Name(s): Alpha-L-fucosidase I | a-L-fucosidase 1 | Tissue alpha-L-fucosidase | tissue fucosidase | alpha-L-Fucosidase I | alpha-L-fucosidase I | alpha-L-fucoside fucohydrolase 1 | FUCA | alpha-L-Fucoside fucohydrolase 1 | I+/--L-fucosidase 1 | Alpha-L-fucoside fucohydrolase 1 | fucosidase, alpha-L- 1, tissue | alpha-L-Fucoside fucohydrolase | FUCO_HUMAN | alpha-L-fucosidase 1 | FUCA1 variant 1 | Alpha-L-fucosidase 1 | alpha-L-Fucosidase 1

Understanding FUCA1: Key To Understanding Fucosidic Pathway and Disease

FUCA1 (Alpha-L-fucosidase I) is a protein that is expressed in various tissues throughout the body, including the liver, spleen, and muscle. It is a key enzyme in the fucosidic pathway, which is a process that breaks down fucosin, a type of sugar found in many plants and animals.

The fucosidic pathway is a crucial aspect of cellular metabolism, as it is involved in the breakdown of a wide variety of substances, including carbohydrates, lipids, and nucleic acids. Fucosin is a key component of these breakdown processes, and FUCA1 is the enzyme that is responsible for breaking down fucosin in the fucosidic pathway.

FUCA1 is a transmembrane protein that is expressed in the liver, spleen, and muscle. It is a glycophosphate hydrolase, which means that it is involved in the breakdown of glycophosphate bonds. In addition to its role in the fucosidic pathway, FUCA1 is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway.

FUCA1 has also been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of FUCA1 are associated with poor prognosis in patients with colorectal cancer. In addition, FUCA1 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Despite these promising findings, much more research is needed to fully understand the role of FUCA1 in diseases. One potential approach to studying FUCA1 is to use it as a drug target or biomarker. By targeting FUCA1 with small molecules or other compounds, researchers may be able to interfere with its function and study its effects on disease. This could lead to the development of new treatments for a variety of diseases.

Another approach to studying FUCA1 is to use it as a model for understanding the fucosidic pathway and its regulation. By studying the structure and function of FUCA1, researchers may be able to gain insights into how fucosin is broken down and how this process is regulated in the body. This knowledge could be useful in the development of new strategies for treating diseases that involve the fucosidic pathway.

Overall, FUCA1 is a complex and important protein that is involved in a wide variety of cellular processes in the body. Its role in the fucosidic pathway and its potential as a drug target or biomarker make it an attractive target for further research. As research continues, it is likely that the functions of FUCA1 will be revealed, and its role in disease will be better understood.

Protein Name: Alpha-L-fucosidase 1

Functions: Alpha-L-fucosidase is responsible for hydrolyzing the alpha-1,6-linked fucose joined to the reducing-end N-acetylglucosamine of the carbohydrate moieties of glycoproteins

The "FUCA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FUCA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 | GABRB1 | GABRB2 | GABRB3 | GABRD | GABRE | GABRG1 | GABRG2 | GABRG3 | GABRG3-AS1 | GABRP | GABRQ | GABRR1